

# CITATION REPORT

List of articles citing

**Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate**

**DOI: 10.2165/00003088-200847050-00001**  
**Clinical Pharmacokinetics, 2008, 47, 285-95.**

**Source:** <https://exaly.com/paper-pdf/43859229/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
503	Dabigatran etexilate. <b>2008</b> , 68, 1699-709		67
502	[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics]. <b>2008</b> , 131 Suppl 2, 66-9		2
501	Dabigatran etexilate: an oral direct thrombin inhibitor. <b>2008</b> , 5, 685-695		9
500	Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen. <b>2009</b> , 15 Suppl 1, 17S-24S		7
499	Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. <b>2009</b> , 31, 194-212		64
498	Farmacocintica y farmacodinamia de los nuevos anticoagulantes orales. <b>2009</b> , 33, 125-133		9
497	Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. <b>2009</b> , 60, 3455-64		83
496	Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. <b>2009</b> , 7, 1313-20		67
495	[New oral anticoagulants: a multidisciplinary approach]. <b>2009</b> , 133, 508-12		1
494	Pharmacokinetics and pharmacodynamics of the new oral anticoagulants. <b>2009</b> , 33, 125-133		
493	Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 1-22	6.2	404
492	Dabigatran versus warfarin in patients with atrial fibrillation. <b>2009</b> , 361, 1139-51		7909
491	Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. <b>2009</b> , 15 Suppl 1, 9S-16S		224
490	Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. <b>2009</b> , 9, 59-68		77
489	Dabigatran etexilate: a guide to its use in preventing venous thromboembolic events. <b>2009</b> , 25, 5-7		
488	[Anticoagulants drugs direct trombin inhibitors]. <b>2009</b> , 28, S3-7		4
487	[Dabigatran: clinical pharmacology]. <b>2009</b> , 28, S8-14		5

486	Antithrombotic therapy in cardiac embolism. <b>2010</b> , 6, 227-37	7
485	New oral anticoagulants: a practical guide for clinicians. <b>2010</b> , 29, 182-91	31
484	[Dabigatran induced exanthema]. <b>2010</b> , 210, 590-1	1
483	New oral antithrombotics: a need for laboratory monitoring. <i>For.</i> <b>2010</b> , 8, 621-6	66
482	Does dabigatran improve stroke-prevention in atrial fibrillation? Reply to a rebuttal. <b>2010</b> , 8, 1438-1439	2
481	New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. <b>2010</b> , 2010, 280731	1
480	Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. <b>2010</b> , 38, 1567-75	62
479	Emerging anticoagulants for venous thromboembolism prevention. <b>2010</b> , 67, S17-25	5
478	Will warfarin ever be replaced?. <b>2010</b> , 15, 210-9	8
477	Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. <b>2010</b> , 30, 1885-9	164
476	Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. <b>2010</b> , 122, 2246-53	138
475	Anticoagulation in the Elderly. <b>2010</b> , 3, 3543-3569	19
474	Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. <b>2010</b> , 41, 1307-9	15
473	Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. <b>2010</b> , 27, 999-1015	348
472	Oral IIa inhibitors. <b>2010</b> , 24, 739-53, ix	5
471	Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. <b>2010</b> , 56, 2067-76	53
470	Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. <b>2010</b> , 126, 175-82	120
469	Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. <i>Clinical Pharmacokinetics</i> , <b>2010</b> , 49, 259-68 <sup>6.2</sup>	554

468	Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?. <b>2010</b> , 28, 295-301	7
467	Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. <b>2010</b> , 11, 1403-11	13
466	Potential of new anticoagulants in patients with cancer. <b>2010</b> , 125 Suppl 2, S30-5	14
465	The new oral anticoagulants. <b>2010</b> , 115, 15-20	218
464	Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. <b>2011</b> , 11, 57-72	32
463	Dabigatran etexilate: a guide to its use in the prevention of thromboembolic disorders. <b>2011</b> , 27, 1-8	
462	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. <b>2011</b> , 9, 279-86	14
461	Dabigatran etexilate: a new oral thrombin inhibitor. <b>2011</b> , 123, 1436-50	284
460	Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. <b>2011</b> , 124, 1573-9	1161
459	[Pharmacologic heterogeneity of new anticoagulants]. <b>2011</b> , 36 Suppl 1, S10-5	2
458	Laboratory assessment of new anticoagulants. <b>2011</b> , 49, 761-72	131
457	Spotlight on dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation. <b>2011</b> , 28, 415-9	1
456	[New antithrombotic drugs for the treatment of venous thromboembolism]. <b>2011</b> , 28, 1008-16	1
455	Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. <b>2011</b> , 25, 215-21	16
454	Dabigatran etexilate: A novel oral direct thrombin inhibitor. <b>2011</b> , 68, 1506-19	39
453	Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation. <b>2011</b> , 150, 4-11	30
452	The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. <b>2011</b> , 127, 497-504	88
451	Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. <b>2011</b> , 127, 457-65	134

450	Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etexilate. <b>2011</b> , 3, CMT.S1176	
449	Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. <b>2011</b> , 6, 2941-51	25
448	Drugs affecting coagulation and platelet function. 912-947	
447	[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future]. <b>2011</b> , 27, 493-500	0
446	Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm. <b>2011</b> , 18, e1-e11	2
445	Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. <b>2011</b> , 75, 800-5	87
444	Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. <b>2011</b> , 75, 1539-47	47
443	[New anticoagulants in the prevention and treatment of venous thromboembolism]. <b>2011</b> , 152, 983-92	2
442	Direct thrombin inhibitors. <b>2011</b> , 72, 581-92	159
441	New anticoagulants: how to deal with treatment failure and bleeding complications. <b>2011</b> , 72, 593-603	39
440	Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. <b>2011</b> , 9, 441-9	26
439	Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. <b>2011</b> , 9, 1652-3	28
438	New anticoagulants for prevention of stroke in patients with atrial fibrillation. <b>2011</b> , 22, 948-55	18
437	The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. <b>2011</b> , 130, 46-58	72
436	Dabigatran after cardiac surgery: caution advised. <b>2011</b> , 142, 1288	7
435	Novel oral anticoagulants and their role in clinical practice. <b>2011</b> , 31, 1175-91	32
434	Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. <b>2011</b> , 31, 1192-207	37
433	Anticoagulant agents in acute coronary syndromes. <b>2011</b> , 36, 127-68	4

432	Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. <b>2011</b> , 123, 131-6	380
431	Dabigatran in atrial fibrillation: pharmacology and clinical trials. <b>2011</b> , 32, 173-80	6
430	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. <b>2011</b> , 31, 326-43	173
429	Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty. <b>2011</b> , 131, 1739-43	5
428	Einsatz von neuen Antikoagulanzen bei kardiovaskulären Erkrankungen. <b>2011</b> , 5, 129-144	
427	Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. <b>2011</b> , 28, 460-72	14
426	Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. <b>2011</b> , 7, 281-7	97
425	Pharmacological basis and clinical evidence of dabigatran therapy. <b>2011</b> , 4, 53	11
424	Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly. <b>2011</b> , 7, 415-23	4
423	Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. <b>2011</b> , 11, 9-25	3
422	Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. <b>2011</b> , 12, 567-77	9
421	Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?. <b>2011</b> , 39, 105-25	3
420	Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. <b>2011</b> , 39, 23-34	3
419	Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin. <b>2011</b> , 19, 154-61	23
418	Update on anti-coagulation in atrial fibrillation. <b>2011</b> , 104, 747-60	5
417	Dabigatran. <b>2011</b> , 46, 196-207	1
416	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. <b>2011</b> , 32, 1968-76, 1976a	42
415	Newer anticoagulants in cardiovascular disease: a systematic review of the literature. <b>2012</b> , 20, 209-21	21

414	Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran. <b>2012</b> , 23, 619-21	4
413	New Oral Anticoagulants. <b>2012</b> , 19, 137-142	
412	Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?. <b>2012</b> , 21, 600-6	23
411	Pharmacologic and nonpharmacologic thromboprophylactic strategies in atrial fibrillation. <b>2012</b> , 1, 225-39	2
410	A review of oral anticoagulants in patients with atrial fibrillation. <b>2012</b> , 124, 7-16	68
409	Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. <b>2012</b> , 25, 150-5	20
408	Thrombosis: simplified. <b>2012</b> , 27 Suppl 2, 12-22	1
407	Novel drugs for oral anticoagulation pharmacotherapy. <b>2012</b> , 10, 473-88	6
406	Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor. <b>2012</b> , 10, 423-7	1
405	Safety of early warfarin resumption following burr hole drainage for warfarin-associated subacute or chronic subdural hemorrhage. <b>2012</b> , 29, 1334-41	30
404	New anticoagulants in atrial fibrillation: an update for clinicians. <b>2012</b> , 3, 37-45	6
403	Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. <b>2012</b> , 46, 1105-10	15
402	Significant Bleeding in Elderly Patient with Atrial Fibrillation Due to Probable Interaction between Dabigatran and Amiodarone. <b>2012</b> , 28, 139-145	
401	Promise and challenges of anticoagulation with dabigatran. <b>2012</b> , 5, 336-8	4
400	Novel anticoagulants in atrial fibrillation stroke prevention. <b>2012</b> , 3, 123-36	15
399	Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. <b>2012</b> , 43, 3442-53	211
398	A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. <b>2012</b> , 107, 775-85	36
397	Dabigatran etexilate for the prevention of stroke in patients with nonvalvular atrial fibrillation. <b>2012</b> , 9, 629-637	

396	New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. <b>2012</b> , 13, 2649-61	8
395	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. <b>2012</b> , 10, 1979-87	24
394	Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. <b>2012</b> , 74, 490-500	85
393	Vitamin K antagonists. Ready to be replaced?. <b>2012</b> , 32, 249-57	8
392	Nouveaux anticoagulants par voie orale: faut-il une surveillance biologique ?. <b>2012</b> , 2012, 9-12	
391	I nuovi anticoagulanti orali e l'anestesia in chirurgia ortopedica maggiore: cosa sappiamo?. <b>2012</b> , 123, 3-5	
390	[Management of direct action oral anticoagulants in the peri-operative period and invasive techniques]. <b>2012</b> , 59, 321-30	19
389	Renal profiles of anticoagulants. <b>2012</b> , 52, 964-75	34
388	Use of anticoagulants in elderly patients. <b>2012</b> , 129, 107-15	42
387	Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. <b>2012</b> , 107, 985-97	277
386	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). <b>2012</b> , 163, 931-937.e1	139
385	Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. <b>2012</b> , 21, 165-73	8
384	Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?. <b>2012</b> , 74, 734-40	13
383	Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. <b>2012</b> , 72, 963-86	19
382	Role of new drugs for management of atrial fibrillation. <b>2012</b> , 46, 1656-70	2
381	Improving prevention and treatment of venous thromboembolism: clinical trial results. <b>2012</b> , 15, 611-22	6
380	Dabigatran in clinical practice. <b>2012</b> , 34, 2051-60	12
379	The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters. <b>2012</b> , 130, 775-9	18



378	Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. <b>2012</b> , 113, 431-41	62
377	Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. <b>2012</b> , 52, 1373-8	66
376	Farmacología de dabigatran y su manejo clínico. <b>2012</b> , 12, 18-24	
375	Anticoagulation Issues in Patients with AF. <b>2012</b> , 4, 363-73	
374	No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. <b>2012</b> , 7, e40804	29
373	Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. <b>2012</b> , 2012, 108983	10
372	Advances in the diagnosis and treatment of acute pulmonary embolism. <b>2012</b> , 4, 9	22
371	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. <b>2012</b> , 8, 139-47	4
370	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e44S-e88S	1112
369	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e531S-e575S	763
368	Dabigatran etexilate: what do hospitalists need to know?. <b>2012</b> , 7, 262-9	4
367	Antithrombotic therapy in patients with chronic kidney disease. <b>2012</b> , 125, 2649-61	92
366	Using dabigatran in patients with stroke: a practical guide for clinicians. <b>2012</b> , 43, 271-9	33
365	[Pharmacology of the new oral anticoagulants]. <b>2012</b> , 37, 362-8	7
364	Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. <b>2012</b> , 124, 340-7	9
363	Management of postoperative atrial fibrillation. <b>2012</b> , 26, 429-37	38
362	New anticoagulants for the prevention of stroke in atrial fibrillation. <b>2012</b> , 26, 47-53	6
361	The use of dabigatran immediately after atrial fibrillation ablation. <b>2012</b> , 23, 264-8	91

360	Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. <b>2012</b> , 34, 766-87	15
359	Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation. <b>2013</b> , 19, 938-43	27
358	Acute stroke management in patients taking dabigatran. <b>2012</b> , 18, 616-22	5
357	Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. <b>2012</b> , 33, 22-7	7
356	Oral anticoagulant-associated intracerebral hemorrhage. <b>2012</b> , 259, 212-24	76
355	Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. <b>2013</b> , 11, 10	112
354	New oral anticoagulants: discussion on monitoring and adherence should start now!. <b>2013</b> , 11, 8	49
353	Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. <b>2013</b> , 23, 4779-84	10
352	A review of current agents for anticoagulation for the critical care practitioner. <b>2013</b> , 28, 763-74	2
351	Stroke Prevention in Atrial Fibrillation. <b>2013</b> , 1, 98-104	
350	Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects. <b>2013</b> , 33, 333-42	6
349	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. <b>2013</b> , 67, 516-26	16
348	Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. <b>2013</b> , 44, e221-5	21
347	Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. <b>2013</b> , 15, 1412-20	52
346	A specific antidote for dabigatran: functional and structural characterization. <b>2013</b> , 121, 3554-62	461
345	New oral anticoagulants and regional anaesthesia. <b>2013</b> , 111 Suppl 1, i96-113	62
344	Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?. <b>2013</b> , 1, 208-216	3
343	Novel anticoagulants and laboratory testing. <b>2013</b> , 35, 262-8	36

342	Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. <b>2013</b> , 106, 382-93	214
341	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. <b>2013</b> , 36, 163-74	15
340	Ischemic stroke in an obese patient receiving dabigatran. <b>2013</b> , 368, 2440-2	39
339	Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. <b>2013</b> , 74, 485-491	
338	Oral anticoagulants to reduce the risk of stroke in atrial fibrillation: how should a clinician choose?. <b>2013</b> , 36, 663-70	3
337	New avenues for anticoagulation in atrial fibrillation. <b>2013</b> , 93, 68-77	20
336	Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. <b>2013</b> , 10, 483-9	115
335	Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. <b>2013</b> , 22, 50-5	15
334	Drug treatment of acute ischemic stroke. <b>2013</b> , 13, 57-69	57
333	Eficacia comparativa y costo-eficacia de los nuevos anticoagulantes orales para prevención de accidente cerebrovascular en pacientes con fibrilación auricular no valvular. <b>2013</b> , 5, 228-232	
332	Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa). <b>2013</b> , 31, 455.e3-5	11
331	Dabigatran pharmacokinetics--implications for treatment. <b>2013</b> , 62, 180	1
330	Managing bleeding in anticoagulated patients in the emergency care setting. <b>2013</b> , 45, 467-77	20
329	Nuevos anticoagulantes orales y su papel en la práctica clínica. <b>2013</b> , 13, 33-41	1
328	Dental management considerations for a patient taking dabigatran etexilate: a case report. <b>2013</b> , 116, e191-5	27
327	Managing blunt trauma in patients receiving dabigatran etexilate: case study and review of the literature. <b>2013</b> , 39, 302-8	3
326	Thrombin inhibitors: surgical considerations and pharmacology. <b>2013</b> , 83, 215-21	8
325	Implications of new anticoagulants in primary practice. <b>2013</b> , 67, 139-56	13

324	Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. <b>2013</b> , 109, 596-605	156
323	Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. <b>2013</b> , 12, 394-405	44
322	The novel anticoagulants: the surgeons' prospective. <b>2013</b> , 153, 303-7	4
321	New oral anticoagulants in elderly patients with atrial fibrillation. <b>2013</b> , 126, 289-96	29
320	Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. <b>2013</b> , 33, 409-18	38
319	Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. <b>2013</b> , 62, 591-4	35
318	Removal of dabigatran by hemodialysis. <b>2013</b> , 61, 487-9	129
317	Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital. <b>2013</b> , 36, 280-5	16
316	Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. <b>2013</b> , 110, 162-72	118
315	Dabigatran: is there a role for coagulation assays in guiding therapy?. <b>2013</b> , 47, 828-40	8
314	Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. <b>2013</b> , 8, 1533-9	75
313	Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. <b>2013</b> , 11, 1493-502	157
312	Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. <b>2013</b> , 69, 1875-81	93
311	Oral bioavailability of dabigatran etexilate (Pradaxa <sup>®</sup> ) after co-medication with verapamil in healthy subjects. <b>2013</b> , 75, 1053-62	117
310	Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. <b>2013</b> , 168, 2540-7	40
309	Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. <b>2013</b> , 37, 233-9	27
308	Pharmacology of the new target-specific oral anticoagulants. <b>2013</b> , 36, 133-40	34
307	Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. <b>2013</b> , 8, e49-e50	7

306	Management of New Anticoagulants in the ICU. <b>2013</b> , 4, 326-331	
305	The pharmacology and therapeutic use of dabigatran etexilate. <b>2013</b> , 53, 1-13	18
304	New oral anticoagulants for stroke prevention in atrial fibrillation: more choices bring more challenges. <b>2013</b> , 48, 366-71	1
303	Case report: dabigatran-associated gynecologic bleeding. <b>2013</b> , 48, 227-30	6
302	Dabigatran bleed risk with closed head injuries: are we prepared?. <b>2013</b> , 119, 760-5	32
301	Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease. <b>2013</b> , 2013, 131395	11
300	Dabigatran: a cause of hematologic emergency. <b>2013</b> , 346, 190-3	14
299	New oral therapies for the prevention and treatment of venous thromboembolism. <b>2013</b> , 70, 113-25	4
298	Acute pulmonary emboli in a patient on long-term dabigatran therapy. <b>2013</b> , 47, e20	5
297	Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. <b>2013</b> , 125, 34-44	10
296	Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. <b>2013</b> , 76, 776-86	208
295	Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. <b>2013</b> , 53, 456-8	4
294	Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. <b>2013</b> , 11, 1461-71	2
293	Catheter ablation for atrial fibrillation in the elderly. <b>2013</b> , 10, 493-502	
292	Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. <b>2013</b> , 98, 549-54	29
291	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. <b>2013</b> , 9, 207-28	18
290	New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. <b>2013</b> , 2013, 973710	12
289	The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. <b>2013</b> , 9, 341-52	13

288 Hemostatic Aspects of Cardiovascular Medicine. **2013**, 342-394

287	Do novel oral anticoagulants do better than standard therapy in the treatment of deep vein thrombosis?. <b>2013</b> , 33, 218-24	2
286	Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. <b>2014</b> , 29, 2228-34	73
285	Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. <b>2014</b> , 52, 283-7	16
284	The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. <b>2014</b> , 30, 2179-90	3
283	What is the role of hemodialysis for dabigatran-associated major bleeding?. <b>2014</b> , 2014, 514-7	0
282	Anticoagulants and acute kidney injury: clinical and pathology considerations. <b>2014</b> , 33, 174-80	26
281	A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. <b>2014</b> , 78, 599-609	21
280	Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. <b>2014</b> , 12, 1636-46	113
279	Orale Antikoagulanzen bei Patienten mit chronischer Niereninsuffizienz. <b>2014</b> , 9, 442-446	
278	Which drug should we use for stroke prevention in atrial fibrillation?. <b>2014</b> , 29, 293-300	6
277	Increased risk of myocardial infarction with dabigatran: fact or fiction?. <b>2014</b> , 15, 19-26	7
276	Poor Efficacy of Haemodiafiltration to Treat Dabigatran-Associated Coagulopathy. <b>2014</b> , 15, 154-157	0
275	Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. <b>2014</b> , 10, 627-39	16
274	The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. <b>2014</b> , 29, 143-51	61
273	Protecting the brain and the heart: antithrombotic treatment in nonvalvular atrial fibrillation. <b>2014</b> , 65, 372-8	1
272	The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). <b>2014</b> , 63, 321-8	585
271	Direct oral anticoagulants--pharmacology, drug interactions, and side effects. <b>2014</b> , 51, 89-97	31

270	The newer anticoagulants in thrombosis control in cancer patients. <b>2014</b> , 41, 339-45	4
269	Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. <b>2014</b> , 134, 227-33	15
268	Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fibrillation. <b>2014</b> , 30, 478-484	10
267	The pharmacology of novel oral anticoagulants. <b>2014</b> , 37, 217-33	45
266	Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. <b>2014</b> , 35, 1836-43	15
265	Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. <b>2014</b> , 171, 1043-53	31
264	Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers. <b>2014</b> , 42, 250-6	31
263	Latest developments in anticoagulant drug discovery. <b>2014</b> , 19, 921-35	5
262	Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. <b>2014</b> , 167, 810-7	165
261	Interpretation of coagulation test results under direct oral anticoagulants. <b>2014</b> , 36, 261-8	17
260	Protocol in managing oral surgical patients taking dabigatran. <b>2014</b> , 59, 296-301; quiz 401	44
259	Economic implications of inadequate treatment of venous thromboembolism and potential solutions. <b>2014</b> , 27, 178-86	5
258	Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50µ rat plasma and its application to pharmacokinetic study. <b>2014</b> , 973C, 110-119	17
257	A Novel One-pot Synthesis of 3-[(3-Amino-4-methylaminobenzoyl pyridin-2-yl)amino]propionic Acid Ethyl Ester. <b>2014</b> , 46, 376-380	1
256	Anticoagulation for noncardiac indications in neurologic patients: comparative use of non-vitamin k oral anticoagulants, low-molecular-weight heparins, and warfarin. <b>2014</b> , 16, 309	5
255	Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. <b>2014</b> , 48, 734-40	59
254	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. <b>2014</b> , 148, 772-91	47
253	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. <b>2014</b> , 148, e153-93	170

252	Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. <b>2014</b> , 74, 1785-800	19
251	What is the role of renal replacement therapy in the setting of dabigatran toxicity?. <b>2014</b> , 27, 223-6	2
250	[Direct anticoagulants for atrial fibrillation. Update 2014]. <b>2014</b> , 39, 357-67; quiz 368	2
249	Potential use of NOACs in developing countries: pros and cons. <b>2014</b> , 70, 817-28	12
248	Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?. <b>2014</b> , 15, 1991-2001	9
247	New oral anticoagulants in practice: pharmacological and practical considerations. <b>2014</b> , 14, 175-89	52
246	Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. <b>2014</b> , 42, 201-6	63
245	Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. <b>2014</b> , 39, 118-35	22
244	An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. <b>2014</b> , 54, 901-9	21
243	Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation. <b>2014</b> , 30, 58-64	5
242	Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. <b>2014</b> , 112, 419-20	14
241	Dental implications of new oral anticoagulants for atrial fibrillation. <b>2014</b> , 41, 526-8, 530-1	10
240	Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation. <b>2015</b> , 31, 183-8	9
239	Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. <b>2015</b> , 40, 183-212	183
238	Determinazione dei farmaci anticoagulanti orali diretti in regime di urgenza. <b>2015</b> , 11, 157-164	
237	Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation. <b>2015</b> , 117, 323-9	28
236	Analysis of the influence of dabigatran on coagulation factors and inhibitors. <b>2015</b> , 37, 225-30	4
235	A New Generation of Antiplatelet, and Anticoagulant Medication and the Implications for the Dental Surgeon. <b>2015</b> , 42, 840-2, 845-6, 849-50 passim	7



234	Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. <b>2015</b> , 35, 560-8	27
233	Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. <b>2015</b> , 9, 3557-69	
232	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. <b>2015</b> , 10, 1431-44	14
231	A Study of the Management of Patients Taking Novel Oral Antiplatelet or Direct Oral Anticoagulant Medication Undergoing Dental Surgery in a Rural Setting. <b>2015</b> , 3, 102-110	3
230	Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack. <b>2015</b> , 68, 16-21	8
229	A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. <b>2015</b> , 113, 943-51	205
228	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <b>2015</b> , 114, 198-205	119
227	Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. <b>2015</b> , 132, 194-204	167
226	Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. <b>2015</b> , 53, 156-63	28
225	Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men. <b>2015</b> , 45, 663-71	3
224	New oral anti-coagulants: Implications for neurosurgery. <b>2015</b> , 29, 182-8	2
223	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. <b>2015</b> , 169, 315-22	8
222	Enhanced elimination of dabigatran through extracorporeal methods. <b>2015</b> , 11, 85-95	13
221	Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. <b>2015</b> , 8, 199-201	6
220	Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. <b>2015</b> , 115, 1696-9	13
219	Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. <b>2015</b> , 139, 665-73	98
218	New oral anticoagulants: a practical guide for physicians. <b>2015</b> , 1, 134-45	40
217	Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. <b>2015</b> , 135, 1070-4	13

216	Dabigatran for the prevention and treatment of thromboembolic disorders. <b>2015</b> , 13, 529-40	6
215	The evolving role of dabigatran etexilate in clinical practice. <b>2015</b> , 16, 2053-72	
214	Structure-guided residence time optimization of a dabigatran reversal agent. <b>2015</b> , 7, 871-80	8
213	Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. <b>2015</b> , 35, 771-8	19
212	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. <b>2015</b> , 4, e002322	60
211	Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. <b>2015</b> , 88, 95-105	18
210	Predicting toxicities of reactive metabolite-positive drug candidates. <b>2015</b> , 55, 35-54	73
209	Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?. <b>2015</b> , 28, 182-9	13
208	Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate. <b>2016</b> , 46, 99-101	7
207	Dabigatran approaching the realm of heparin-induced thrombocytopenia. <b>2016</b> , 51, 77-87	5
206	Use of novel oral anticoagulant agents in venous thromboembolism. <b>2016</b> , 6, 570-581	10
205	Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery. <b>2016</b> , 2016, 9692568	4
204	Uso de los anticoagulantes orales directos en la práctica clínica. <b>2016</b> , 64, 295	1
203	Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. <b>2016</b> , 116, 461-71	24
202	A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate. <b>2016</b> , 27, 563-7	2
201	Laboratory measurement of the direct oral anticoagulants. <b>2016</b> , 172, 315-36	65
200	Laboratory Monitoring: A Turning Point in the Use of New Oral Anticoagulants. <b>2016</b> , 38, 12-21	11
199	Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis-A simulation analysis. <b>2016</b> , 56, 597-608	6

198	Management of direct oral anticoagulants-associated bleeding in the trauma patient. <b>2016</b> , 29, 220-8	14
197	Novel oral anticoagulants in the management of coronary artery disease. <b>2016</b> , 27, 412-9	4
196	Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. <b>2016</b> , 38, 814-816	
195	A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. <b>2016</b> , 352, 92-106	17
194	Clinical considerations on the posology of direct oral anticoagulants. <b>2016</b> , 216, 384-392	
193	Dabigatran-related axillary hematoma and coagulopathy in a patient with a pacemaker: The lesson we learned from a case report. <b>2016</b> , 7, 47-49	0
192	The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation. <b>2016</b> , 16, 47	3
191	Les anticoagulants oraux directs : analyse des accidents iatrogènes dans le service des urgences de l'hôpital de la Conception. <b>2016</b> , 51, 141-146	
190	Dabigatran malabsorption in amiodarone-induced thyrotoxicosis: a clinical report. <b>2016</b> , 11, 889-90	4
189	Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. <b>2016</b> , 118, 1409-24	76
188	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <b>2016</b> , 39, 739-746	10
187	Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. <b>2016</b> , 222, 615-619	4
186	Clinical considerations on the posology of direct oral anticoagulants. <b>2016</b> , 216, 384-392	
185	Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation. <b>2016</b> , 145, 100-6	6
184	The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency. <b>2016</b> , 6, 29242	17
183	Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. <b>2016</b> , 119, 555-561	26
182	Use of Extracorporeal Techniques in the Removal of Dabigatran. <b>2016</b> , 23, e485-8	
181	Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. <b>2016</b> , 44, 1229-45	70

180	Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism. <b>2016</b> , 29, 392-405	2
179	Synthesis and biological evaluation of novel dabigatran derivatives as thrombin inhibitors. <b>2016</b> , 42, 735-752	1
178	Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS). <b>2016</b> , 1383, 21-7	9
177	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. <b>2016</b> , 95, 437-49	47
176	Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. <b>2016</b> , 139, 128-34	25
175	Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. <b>2016</b> , 16, 171-82	2
174	An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. <b>2016</b> , 45, 618-30	36
173	PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo. <b>2016</b> , 35, 3817-28	31
172	Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations. <b>2016</b> , 53, 446-51	17
171	The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs. <b>2016</b> , 31, 424-30	3
170	The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices. <b>2017</b> , 20, 51-62	42
169	Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. <b>2017</b> , 15, 848-857	17
168	Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. <b>2017</b> , 130, 517-524	57
167	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <b>2017</b> , 189, E325	2
166	Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. <b>2017</b> , 77, 331-344	12
165	Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. <b>2017</b> , 10,	22
164	The Reversal of Direct Oral Anticoagulants in Animal Models. <b>2017</b> , 48, 144-158	3
163	pH-dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability. <b>2017</b> , 105, 82-90	28

162	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <b>2017</b> , 189, E4-E10	34
161	Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. <b>2017</b> , 18, 467-477	6
160	Anticoagulant Reversal and Anesthetic Considerations. <b>2017</b> , 35, 191-205	4
159	Why Prodrugs and Propeptides Succeed. <b>2017</b> , 30, 1117-1126	23
158	Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report. <b>2017</b> , 28, 576-579	13
157	Gender differences in the effects of cardiovascular drugs. <b>2017</b> , 3, 163-182	126
156	Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile. <b>2017</b> , 86, 75-83	6
155	Direct Oral Anticoagulants: An Overview for the Interventional Radiologist. <b>2017</b> , 40, 321-330	5
154	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. <b>2017</b> , 15, 2377-2387	15
153	Anticoagulation: The Successes and Pitfalls of Long-Term Management. <b>2017</b> , 2, 603-622	
152	Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults. <b>2017</b> , 65, 2405-2412	23
151	Dabigatran-Induced Massive Spontaneous Hemothorax. <b>2017</b> , 4, 12	4
150	Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs. <b>2017</b> , 40, 1091-1098	7
149	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. <b>2017</b> , 377, 431-441	639
148	Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation. <b>2017</b> , 136, 215-221	3
147	Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants. <b>2017</b> , 10, 163-185	25
146	Direct oral anticoagulant considerations in solid organ transplantation: A review. <b>2017</b> , 31, e12873	27
145	An injectable in situ lipid phase transition system for sustained delivery of dabigatran etexilate with low burst release. <b>2017</b> , 7, 56594-56601	2

144	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Society, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. <b>2017</b> , 1, 202-215	75
143	Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report. <b>2017</b> , 15, 23	11
142	Drug-induced liver injury: Towards early prediction and risk stratification. <b>2017</b> , 9, 30-37	16
141	Transitioning Between Anticoagulants. <b>2018</b> , 133-150	21
140	Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. <b>2018</b> , 2, 347-356	5
139	Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin. <b>2018</b> , 104, 1182-1190	38
138	State of play and future direction with NOACs: An expert consensus. <b>2018</b> , 106, 9-21	7
137	Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature. <b>2018</b> , 45, 588-592	2
136	The expanding role of prodrugs in contemporary drug design and development. <b>2018</b> , 17, 559-587	273
135	The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination. <b>2018</b> , 24, 724-733	9
134	Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). <b>2018</b> , 43, 263-309	372
133	Dental implant surgery in patients in treatment by dabigatran. <b>2018</b> , 29, 644-648	24
132	Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury. <b>2018</b> , 71, 137-141	11
131	Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation. <b>2018</b> , 22, 165-173	8
130	Interventional Pain Procedures in Patients on Anticoagulants. <b>2018</b> , 805-812.e2	1
129	Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network. <b>2018</b> , 2, 37-49	1
128	Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion. <b>2018</b> , 7, e010854	4
127		

126	Therapeutic Drug Monitoring of Antidepressants. <b>2019</b> , 250, 115-133	8
125	Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots. <b>2018</b> , 2, 696-707	7
124	Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). <b>2018</b> , 135, 60-79	57
123	Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. <b>2018</b> , 13, 3145-3161	59
122	Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design. <b>2018</b> , 2, 580-590	3
121	A Narrative Review for Perioperative Physicians of the 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <b>2019</b> , 33, 290-301	2
120	Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation. <b>2019</b> , 103, 847-862	5
119	Intracerebral Hemorrhage in the Neurocritical Care Unit. <b>2019</b> , 129-145	
118	Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. <b>2019</b> , 12, 781-790	6
117	Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy. <b>2019</b> , 10, 966	9
116	Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain. <b>2019</b> , 33, e13748	4
115	Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications. <b>2019</b> , 35, 326-340	10
114	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <b>2019</b> , 74, 1760-1768	12
113	Dabigatran must be used carefully: literature review and recommendations for management of adverse events. <b>2019</b> , 13, 1527-1533	13
112	The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study. <b>2019</b> , 14, e0217302	8
111	New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report. <b>2019</b> , 55,	1
110	Management of severe congenital protein C deficiency with a direct oral anticoagulant, edoxaban: A case report. <b>2019</b> , 66, e27686	9
109	Ischemic stroke during anticoagulant interruption by healthcare professionals in stroke patients with atrial fibrillation. <b>2019</b> , 400, 113-118	4

108	Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. <b>2019</b> , 47, 487-494	10
107	Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: A case for apixaban. <b>2019</b> , 30, 718-722	11
106	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. <b>2019</b> , 15, 381-398	21
105	Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?. <b>2019</b> , 75, 875-877	6
104	Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etxilate, a Prototypical P-gp Substrate. <b>2019</b> , 60, 586	
103	Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. <b>2019</b> , 44, 1-12	28
102	A level-headed approach to measuring direct oral anticoagulants: A 2-year retrospective analysis of DOAC levels from a tertiary UK centre. <b>2019</b> , 41, 200-207	5
101	Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage. <b>2019</b> , 50, 529-536	15
100	Pharmacology of Oral Anticoagulants. <b>2019</b> , 11-34	1
99	Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. <b>2020</b> , 37, 3916-3928	
98	Identify thrombin inhibitor with novel skeleton based on virtual screening study. <b>2020</b> , 1-9	0
97	Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. <b>2020</b> , 12,	6
96	Pharmacokinetics and Safety of Dabigatran Etxilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. <b>2020</b> , 45, 601-609	3
95	A composite nanocarrier to inhibit precipitation of the weakly basic drug in the gastrointestinal tract. <b>2020</b> , 27, 712-722	1
94	New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl Glucuronides. <b>2020</b> , 33, 1551-1560	8
93	Re: Safety of direct oral anticoagulant - and antiplatelet therapy in patients with atrial fibrillation treated by carotid artery stenting. <b>2020</b> , 29, 105028	
92	Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling. <b>2020</b> , 10, 9717	
91	Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience. <b>2020</b> , 2020, 6927423	2



90	Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. <b>2020</b> , 1-12	1
89	Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions. <b>2020</b> , 8, e00593	0
88	Coagulopathy reversal in intracerebral haemorrhage. <b>2020</b> , 5, 29-33	2
87	Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. <b>2020</b> , 135, 491-504	36
86	Impact of bariatric surgery on oral anticoagulants pharmacology, and consequences for clinical practice: a narrative review. <b>2021</b> , 35, 53-61	4
85	Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood. <b>2021</b> , 37, 101-107	
84	Binding of direct oral anticoagulants to the FA1 site of human serum albumin. <b>2021</b> , 34, e2877	3
83	A chemometric comparison of different models in fluorescence analysis of dabigatran etexilate and dabigatran. <b>2021</b> , 246, 118988	2
82	Cardiovascular Medications. <b>2021</b> , 597-642	1
81	Pharmacogenetics of Direct Oral Anticoagulants.	0
80	Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. <b>2021</b> , 19, 1259-1270	1
79	Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants. <b>2021</b> , 9,	3
78	Bacteriocins: Potential for Human Health. <b>2021</b> , 2021, 5518825	9
77	Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). <b>2021</b> , 9,	7
76	A case of a markedly elevated dabigatran concentration resistant to the approved dose of idarucizumab. <b>2021</b> , 51, 616-617	
75	Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. <b>2021</b> , 9,	7
74	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <b>2021</b> , 23, 1612-1676	99
73	Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. <b>2021</b> , 30, 1027-1036	1

72	Advances in reconstructing intestinal functionalities in vitro: From two/three dimensional-cell culture platforms to human intestine-on-a-chip. <b>2021</b> , 226, 122097	3
71	Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems. <b>2021</b> , 2, 98-117	1
70	Development and Validation of UPLC-MS/MS Method for the determination of Rivaroxaban in human plasma using Liquid-liquid extraction. <b>2021</b> , 3239-3243	2
69	Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. <b>2021</b> , 19, 2583-2595	0
68	Analysis of the clinical characteristics of dabigatran-induced oesophagitis. <b>2021</b> ,	
67	The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants. <b>2021</b> , 22,	5
66	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. <b>2021</b> , 17, 1091-1102	0
65	Development and validation of LC-MS/MS method for simultaneous determination of dabigatran etexilate and its active metabolites in human plasma, and its application in a pharmacokinetic study. <b>2021</b> , 203, 114220	1
64	Human Variability in Carboxylesterases and carboxylesterase-related Uncertainty Factors for Chemical Risk Assessment. <b>2021</b> , 350, 162-170	1
63	Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. <b>2021</b> , 165, 105932	1
62	Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. <b>2021</b> , 8, e22-e33	24
61	Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. <b>2020</b> , 42, 2066-2081.e9	2
60	A dabigatran etexilate phospholipid complex nanoemulsion system for further oral bioavailability by reducing drug-leakage in the gastrointestinal tract. <b>2017</b> ,	22
59	Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors. <b>2012</b> , 7, e34354	19
58	A Case of Liver Failure Due to Dabigatran Treated with Venovenous Hemodiafiltration and Idarucizumab. <b>2020</b> , 15, 227-230	2
57	DO WE KNOW ALL ABOUT PREVENTION OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPEDIC SURGERY?. <b>2018</b> , 24, 129-143	7
56	Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran. <b>2012</b> , 35, e1286-9	6
55	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. <b>2015</b> , 7, 115-31	8

54	Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. <b>2014</b> , 4, 314-23	9
53	Beyond warfarin: The advent of new oral anticoagulants. <b>2015</b> , 25, 375-9	6
52	A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. <b>2013</b> , 8, 1052-60	45
51	Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function. <b>2014</b> , 2, 18-22	1
50	Recent progress in antithrombotic therapy for atrial fibrillation. <b>2011</b> , 18, 257-73	3
49	Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. <b>2021</b> , 195, 790-801	0
48	In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism. <b>2009</b> , 32, 35	
47	Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art. <b>2009</b> , 29-38	0
46	Compendio de fármacos que alteran la hemostasia. <b>2010</b> , 97-111	
45	Enfermedad tromboembólica venosa y anestesia. <b>2010</b> , 113-121	
44	2. Pharmacokinetics and Drug Interaction of New Anticoagulants: Direct Thrombin Inhibitor and Factor Xa Inhibitors. <b>2011</b> , 42, 305-313	
43	A review from clinical viewpoint. <b>2011</b> , 22, 156-163	
42	Enoxaparin and Dabigatran Thromboprophylaxis after Total Hip Arthroplasty. <b>2011</b> , 18, 67-70	1
41	Prevention of Venous Thromboembolism in Knee Surgery. <b>2012</b> , e137-1-e137-6	
40	Advances in Anticoagulation for Total Joint Arthroplasty: The Newer Agents. <b>2012</b> , e142-1-e142-7	
39	Atrial Fibrillation: Current and Forthcoming Antithrombotic Therapies. 285-305	
38	Non-surgical Treatment and Prevention of Atrial Fibrillation. <b>2013</b> , 543-559	
37	Use of Dabigatran Etxelate for Prevention of Venous Thromboembolic Complications in Long Bone Fractures. <b>2015</b> , 70-75	

36	Use of Dabigatran Etexilate for Prevention of Venous Thromboembolic Complications in Long Bone Fractures. <b>2015</b> , 22, 70-75	
35	Efficacy and Transesophageal Echocardiographic Findings of Short-term Dabigatran or Rivaroxaban Therapy for Electrical Cardioversion in Patients with Atrial Fibrillation. <b>2015</b> , 16, 134-140	1
34	Risk management of direct oral anticoagulant administration: An approach from the clinical laboratory. <b>2016</b> , 19, 81-89	
33	Drug-induced Reduction of Gamma Carboxylation in Osteocalcin: What is the Fallback?. <b>2019</b> , 11, e5504	1
32	Perioperative management of patients receiving long-term antithrombotic therapy. Clinical practice recommendations of the national Federation of Anesthesiologists and Reanimatologists. <b>2021</b> , 7-26	
31	Reversión de anticoagulantes orales directos: una perspectiva desde Urgencias. <b>2020</b> , 23, 483-490	
30	New options in anticoagulation for the prevention of venous thromboembolism and stroke. <b>2011</b> , 36, 86-99	5
29	Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. <b>2011</b> , 36, 518-28	1
28	Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. <b>2010</b> , 1, e0111	1
27	Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. <b>2014</b> , 4, 224-31	8
26	Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. <b>2014</b> , 7, 376-84	25
25	Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. <b>2014</b> , 10, 292-7	7
24	Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity.. <b>2022</b> , 24, 88-97	1
23	Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits.. <b>2022</b> , 17, 1-9	
22	Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran.. <b>2022</b> , 14,	1
21	Systematic Review of Drug-drug Interactions between Rifamycins and Anticoagulant and Antiplatelet Agents and Considerations for Management.. <b>2022</b> ,	1
20	The value and limitations of new oral anticoagulant plasma level assessments.. <b>2022</b> , 24, A32-A41	0
19	Peculiarities of dabigatran pharmacogenetics: literature review. <b>2022</b> , 29, 39-44	

- 18 Development and Validation of UPLC-MS/MS Method for Quantifying of Free and Total Dabigatran in Human Plasma: An Application for a Bioequivalence Study.. **2022**, e5382
- 17 Biopharmaceutics considerations for direct oral anticoagulants.. **2022**, 1-14
- 16 The Application of Biopharmaceutics Classification Systems to Modified-Release Formulations. **2022**, 103-117
- 15 Impact of different renal function equations on direct oral anticoagulant concentrations.. **2021**, 11, 23833 ○
- 14 Anticoagulants in Use. **2022**, 327-345
- 13 Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients. **2022**, 3, 208-218
- 12 Direct oral anticoagulants after bariatric surgery [what is the evidence?]. ○
- 11 Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials. ○
- 10 Twice- or once-daily dosing of direct oral anticoagulants and gastrointestinal bleeding in patient with atrial fibrillation. **2022**, 22, 100203 ○
- 9 Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations.. **2022**, ○
- 8 Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation. **2022**, 100479 ○
- 7 Clinical conundrums involving statin drug-drug interactions. **2022**, ○
- 6 Direct Oral Anticoagulants. An Updated Systematic Review of its Clinical Pharmacology and Clinical Effectiveness and Safety in Patients with Nonvalvular Atrial Fibrillation. ○
- 5 Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects. **2023**, 16, 364 ○
- 4 Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. **2023**, 62, 351-373 ○
- 3 Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. **2023**, 37, 203-214 ○
- 2 Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation. **2023**, ○
- 1 General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro Data. ○

